Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Debu, Tripathy"'
Autor:
Pascal Finetti, Ginette S Santiago-Sánchez, Steven Van Laere, Xiaoding Hu, Bisrat G. Debeb, Debu Tripathy, François Bertucci, Wendy A. Woodward, Juhee Song, Naoto T. Ueno, Richard A. Larson, Savitri Krishnamurthy, Kristen Gomez, Emilly S. Villodre, Wintana Balema, Pablo E. Vivas-Mejia, Xiaoping Su, Shane R. Stecklein
Publikováno v:
Molecular Oncology
Molecular Oncology, Vol 15, Iss 10, Pp 2752-2765 (2021)
Molecular Oncology, 2021, 15 (10), pp.2752-2765. ⟨10.1002/1878-0261.13074⟩
Molecular Oncology, Vol 15, Iss 10, Pp 2752-2765 (2021)
Molecular Oncology, 2021, 15 (10), pp.2752-2765. ⟨10.1002/1878-0261.13074⟩
Inflammatory breast cancer (IBC) is an aggressive form of primary breast cancer characterized by rapid onset and high risk of metastasis and poor clinical outcomes. The biological basis for the aggressiveness of IBC is still not well understood and n
Autor:
Hak-Sung Kim, James M. Reuben, Evan N. Cohen, Debu Tripathy, Chandra Bartholomeusz, Naoto T. Ueno, Yoo-Kyoung Sohn, Gaurav B. Chauhan, Morgan M. Green, Geoffrey Bartholomeusz, Savitri Krishnamurthy, Lakesla R. Iles, Moises J. Tacam, Venkata Lokesh Battula, Maria Gagliardi, Jihyun Park, Xiaoping Wang, Natalie W. Fowlkes
Publikováno v:
Breast Cancer Research and Treatment
Background Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype that lacks targeted therapies. Patients with TNBC have a very poor prognosis because the disease often metastasizes. New treatment approaches addressing drivers of
Autor:
Debu Tripathy, Zaid Soomro, Ryan Sun, Nuhad K. Ibrahim, Elshad Hasanov, Vicente Valero, Aya Albittar, Omar Alhalabi
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-5 (2021)
NPJ Breast Cancer
NPJ Breast Cancer
The development of brain metastases (BMs) in breast cancer (BC) patients remains a challenging complication. Current clinical practice guidelines recommend local treatment of BMs without changing systemic therapy (CST) in patients with stable extracr
Autor:
Debu Tripathy, Gregory N. Fuller, Chao Gao, Kenneth R. Hess, Sami I. Bashour, Donald F. Schomer, Nuhad K. Ibrahim
Publikováno v:
British Journal of Cancer
BackgroundCNS miliary metastasis (MiM) is poorly recognised in breast and other malignancies. Given its rarity, little epidemiologic, radiographic and clinical data are known. Although usually identified on neuroimaging, criteria for radiographic dia
Autor:
Funda Meric-Bernstam, Debu Tripathy, Bora Lim, Senthil Damodaran, Hui Chen, Qingqing Ding, Aysegul A. Sahin, Weiwei Chen, Rajyalakshmi Luthra, Sarina Anne Piha-Paul
Publikováno v:
Human Pathology. 92:32-38
Summary HER2 mutations have been reported in approximately 2% of breast cancers. Regardless of HER2 overexpression or amplification status, breast cancer with HER2 mutations may respond to HER2-targeted therapy. As HER2 mutation is rare, the clinical
Autor:
Yu-Jeh Liu, Ozan Berk Imir, David J. Shapiro, Yvonne S. Ziegler, Qianying Zuo, Jenny Drnevich, Evelyn Aranda, Zeynep Madak-Erdogan, Ashlie Santaliz Casiano, C. Chien, Debu Tripathy, N. H. Park, A. N. Mogol, Eylem Kulkoyluoglu-Cotul, Benita S. Katzenellenbogen, Ben Ho Park, A. S. Raghavendra, John D. O’Neill
Publikováno v:
Mol Cancer Res
Estrogen receptor-positive (ER+) metastatic tumors contribute to nearly 70% of breast cancer-related deaths. Most patients with ER+ metastatic breast cancer (MBC) undergo treatment with the estrogen receptor antagonist fulvestrant (Fulv) as standard-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::194582c788d79991066b0614024b916a
https://doi.org/10.1101/2021.09.07.458711
https://doi.org/10.1101/2021.09.07.458711
Autor:
Rie K. Tahara, JM Reuben, Babita Saigal, Beth Chasen, Diane Liu, Gabriel N. Hortobagyi, T Fujii, Debu Tripathy, Senthil Damodaran, Bora Lim, NT Ueno, Hui Gao, Nuhad K. Ibrahim, Anthony Lucci, Yu Shen
Publikováno v:
Cancer Research. 79:P1-18
Background: Radium-223 dichloride (Ra-223) is a targeted alpha particle-based radiotherapeutic that has a localized cytotoxic effect on bone metastases. We sought to determine whether the circulating tumor cell (CTC) count and the presence of CTCs in
Autor:
Chandra Bartholomeusz, JM Reuben, Debu Tripathy, Venkata Lokesh Battula, Gaurav B. Chauhan, John W. Park, NT Ueno, Evan N. Cohen
Publikováno v:
Cancer Research. 79:P2-06
Background: Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer characterized by a high rate of metastatic recurrence and poor prognosis. Molecular mechanism underlying the metastatic behavior of TNBC has not been well eluc
Autor:
Bisrat G. Debeb, Yun Gong, Xiaoding Hu, Omar M. Rahal, Wendy A. Woodward, Juhee Song, Xiaoping Wang, Richard A. Larson, Emilly S. Villodre, Savitri Krishnamurthy, Debu Tripathy, Naoto T. Ueno
Inflammatory breast cancer (IBC) is a clinically distinct and highly aggressive form of breast cancer with rapid onset and a strong propensity to metastasize. The molecular mechanisms underlying the aggressiveness and metastatic propensity of IBC are
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::de7ab0e8dee42139050be22d8720120c
https://doi.org/10.1101/2020.07.07.190496
https://doi.org/10.1101/2020.07.07.190496
Autor:
Debu Tripathy, Yun Gong, Juhee Song, Wendy A. Woodward, Naoto T. Ueno, Emilly S. Villodre, Richard A. Larson, Savitri Krishnamurthy, Xiaoding Hu, Bisrat G. Debeb, Xiaoping Wang, Omar M. Rahal
Publikováno v:
Communications Biology
Communications Biology, Vol 4, Iss 1, Pp 1-14 (2021)
Communications Biology, Vol 4, Iss 1, Pp 1-14 (2021)
Inflammatory breast cancer (IBC) is a clinically distinct and highly aggressive form of breast cancer with rapid onset and a strong propensity to metastasize. The molecular mechanisms underlying the aggressiveness and metastatic propensity of IBC are